Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116656 | 0.87 | HPGD (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL564309 | 0.87 | CYP2C19 (0.56) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL16001109 | 0.87 | CYP2C19 (0.56) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL13452120 | 0.87 | CYP2C19 (0.56) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL15105859 | 0.87 | HPGD (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL19916997 | 0.87 | HPGD (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL21057283 | 0.87 | HPGD (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL21057304 | 0.87 | HPGD (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL18562169 | 0.86 | ALDH1A1 (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 | |
| SCHEMBL14618064 | 0.86 | ALDH1A1 (0.50) | HPGDALDH1A1TDP1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4117780-B1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INT GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-12441720-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-10-14 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250074855-A1 | STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE | AMGEN INC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025026266-A1 | COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2025-02-06 | — | — | WO | disclosed |
| US-20070005130-A1 | Biodegradable polymer for coating | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1826333-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINB1, SERPINE1 | HPGD 82/4885ALDH1A1 217/4885TDP1 534/4885 |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | HPGD 324/4885ALDH1A1 829/4885TDP1 343/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | HPGD 4152/4885ALDH1A1 2764/4885TDP1 1294/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | HPGD 1610/4885ALDH1A1 3430/4885TDP1 2062/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | HPGD 2022/4885ALDH1A1 3319/4885TDP1 922/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | HPGD 2022/4885ALDH1A1 3319/4885TDP1 922/4885 |
| US-20250074855-A1 | STEREOSELECTIVE PREPARATION OF TRANS HALO CYCLOBUTANE | CYP8B1, HSD11B1, HSD11B2 | HPGD 1105/4885ALDH1A1 999/4885TDP1 3553/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | HPGD 2022/4885ALDH1A1 3319/4885TDP1 922/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HPGD 568/4885ALDH1A1 2882/4885TDP1 2235/4885 |
| US-12441720-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | HPGD 2681/4885ALDH1A1 1454/4885TDP1 1832/4885 |
| US-20070005130-A1 | Biodegradable polymer for coating | MAL2, MGAM, CD44 | HPGD 608/4885ALDH1A1 1734/4885TDP1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.